Ariceum Therapeutics focuses on diagnosis and precision treatment of neuroendocrine and certain other aggressive, hard-to-treat cancers.
Ariceum Therapeutics has raised $25.0M in total funding. The most recent round was Series A. The last funding was announced in April 2023.
Ariceum Therapeutics's investors include Earlybird Venture Capital, Andera Partners, HealthCap, EQT Life Sciences, Pureos Bioventures.
Ariceum Therapeutics is headquartered in Berlin, Germany.
Ariceum Therapeutics focuses on diagnosis and precision treatment of neuroendocrine and certain other aggressive, hard-to-treat cancers.
Ariceum Therapeutics is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Ariceum Therapeutics — Funding & Investors." VCBacked, April 18, 2023, https://www.vcbacked.co/company/ariceum-therapeutics. Accessed September 30, 2026.
VCBacked. (2023). Ariceum Therapeutics — Funding & Investors. Retrieved September 30, 2026, from https://www.vcbacked.co/company/ariceum-therapeutics
{{cite web |title=Ariceum Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/ariceum-therapeutics |website=VCBacked |access-date=September 30, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated